logo
Plus   Neg
Share
Email

Bayer, Daré Bioscience Sign License Agreement On Ovaprene

Bayer and Daré Bioscience Inc. (DARE) entered into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene.

In Monday regular trade, DARE is trading at $2.00, up $1.16 or 139.52 percent.

Bayer may commercialize Daré's investigational contraceptive product, Ovaprene in the United States once approved by the FDA.

The licensing option becomes effective with a payment of $20 million from Bayer to Daré.

Daré might be eligible to receive commercial milestone payments potentially totaling $310 million as well as double-digit tiered royalties on net sales.

As per the deal, Daré will receive an upfront payment and access to Bayer's clinical and market capabilities while retaining control over Ovaprene's development and regulatory approval process.

Daré plans to file an Investigational Device Exemption for Ovaprene in the first half of 2020 and to initiate a pivotal contraceptive effectiveness and safety clinical study of Ovaprene in the second half of 2020.

If successful, Daré expects that study to support marketing approvals of Ovaprene in the U.S., Europe and other countries worldwide.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google CEO Sundar Pichai announced Monday a $10 billion Google for India Digitization Fund to help accelerate India's digital economy. The investment is planned over the next five to seven years through equity investments, partnerships, and operational, infrastructure and ecosystem investments. Logistics solutions provider Hi-Crush Inc. (HCR) announced Monday that it has voluntarily filed petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas. Hi-Crush has also entered into a Restructuring Support Agreement... Analog Devices, Inc. (ADI) and Maxim Integrated Products, Inc. (MXIM) announced Monday that they have entered into a definitive agreement under which ADI will acquire Maxim in an all stock transaction that values the combined enterprise at over $68 billion. The transaction, which was unanimously approved...
Follow RTT